Enhanced in vitro cytotoxicity and cytostasis of the combination of onconase with a proteasome inhibitor.
In proliferating cells the turnover rate of proteins responsible for regulation of the cell cycle progression, namely cyclins and inhibitors of the cyclin-dependent kinases (CDKs) and phosphatases, is rapid and their cellular level is modulated at the transcriptional, translational and/or degradation (via proteasome pathway) stages. Inhibition of proteasome function results in accumulation of rapidly turning over proteins and, thus, causes an imbalance of the cell cycle regulatory components, and loss of their regulatory function. Indeed, it has been shown that proteasome inhibitors perturb the cell cycle progression. Onconase, a novel RNase which has anti-tumor activity and is in clinical trials, has previously been shown to suppress protein synthesis, presumably by degradation of intracellular RNA, preferentially tRNA. By interfering with regulation of expression of cyclins and/or CDK-inhibitors, onconase also may induce the imbalance of these proteins and potentiate the effect of proteasome inhibitors. In the present study, we observed that the combinations of onconase with peptide-aldehyde inhibitors of calpain and proteasome such as the N-acetyl-leucinyl-leucinyl-norleucinal (LLnL) and the N-acetyl-leucinyl-valinyl-phenylalaninal (LVP), but not N-acetyl-leucinyl-leucinyl-methioninal (LLM), were synergistic in suppressing cell proliferation and inducing apoptosis in three human tumor cell lines: A-549 lung adenocarcinoma, DU-145 prostatic carcinoma, and MDA-MB-231 breast carcinoma. The observed cytotoxicity may also be a result of prevention of the induction of the 'survival' genes by the nuclear factor kappaB (NFkappaB) by onconase and proteasome inhibitors. The data indicate that such combinations should be further tested as potential anti-cancer regimens.
Mikulski
S M
SM
Alfacell Corporation, Bloomfield, NJ 07021, USA.
Viera
A
A
Deptala
A
A
Darzynkiewicz
Z
Z
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000633:toxicity*; D002999:Clone Cells / Q000187:drug effects; D003114:Colony-Forming Units Assay; D003546:Cysteine Endopeptidases / Q000187:drug effects*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004357:Drug Synergism; D004527:Egg Proteins / Q000633:toxicity*; D005434:Flow Cytometry; D005562:Formazans / Q000032:analysis; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology; D009097:Multienzyme Complexes / Q000187:drug effects*; D009842:Oligopeptides / Q000494:pharmacology; D046988:Proteasome Endopeptidase Complex; D012260:Ribonucleases / Q000633:toxicity*; D013778:Tetrazolium Salts / Q000032:analysis; D018675:Toxicity Tests; D014407:Tumor Cells, Cultured / Q000166:cytology / Q000187:drug effects
D000970:Antineoplastic Agents; D015853:Cysteine Proteinase Inhibitors; D004527:Egg Proteins; D005562:Formazans; D007976:Leupeptins; D009097:Multienzyme Complexes; D009842:Oligopeptides; D013778:Tetrazolium Salts; C063261:acetylleucyl-leucyl-norleucinal; C069861:calpain inhibitor 2; C079782:MTT formazan; D004317:Doxorubicin; D012260:Ribonucleases; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; C058703:ranpirnase